CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

Ciudad Autonoma Buenos Ares, Argentina

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

    Phase

    2

    Span

    142 weeks

    Sponsor

    GlaxoSmithKline

    Ansan

    Recruiting

  • Efficacy and Safety of Leuprolide Acetate 45 mg in Subjects With Central Precocious Puberty

    Phase

    4

    Span

    151 weeks

    Sponsor

    HanAll BioPharma Co., Ltd.

    Ansan

    Recruiting

  • Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke

    Phase

    N/A

    Span

    313 weeks

    Sponsor

    Seoul National University Hospital

    Ansan

    Recruiting

  • A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis

    This is an investigator-blinded, randomized, multicenter, active-controlled Phase III study for the treatment of anemia in patients with CKD on hemodialysis. Eligible patients will be randomized to efepoetin alfa or darbepoetin alfa at a ratio of 2:1. An unblinded team will prepare and administer the study drug at the dosages decided by the blinded Investigator. The study consists of 3 study periods: - Screening (up to 28 days before Day 1): subjects in screening will continue treatment with epoetin, methoxy polyethylene glycol-epoetin beta, or darbepoetin alfa as per local standard of care. - Treatment: subjects will discontinue any prior erythropoietin analogue and will be randomized to switch to efepoetin alfa or darbepoetin alfa in a 2:1 ratio. The aim of the treatment period is to maintain Hb levels between 10.0 g/dL and 12.0 g/dL. It is recommended that study treatment be administered any time after completion of dialysis if dosing is scheduled on a dialysis day to avoid potential bias on study assessments. • Follow-up (4 weeks) Phone contacts can be done for follow-up for up to Week 56 or at the time of the last patient's Week 56 visit, whichever is shorter.

    Phase

    3

    Span

    192 weeks

    Sponsor

    Genexine, Inc.

    Ansan

    Recruiting

  • A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

    This is a global, multicenter, randomized, double-blind, parallel group, placebo-controlled phase 3 study investigating the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) who are symptomatic despite treatment with non-sedating second generation H1-antihistamines at 1-4 times the locally approved dose. There is a screening period of up to 4 weeks, followed by a 24-week placebo-controlled treatment period, a 28-week active treatment period where all participants receive barzolvolimab followed by a 16-week treatment free period. Approximately 915 adult participants (610 in the active arms and 305 in the placebo arm) will be randomly assigned to the treatment arms.

    Phase

    3

    Span

    147 weeks

    Sponsor

    Celldex Therapeutics

    Ansan

    Recruiting

  • A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects with Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy

    Phase

    1

    Span

    103 weeks

    Sponsor

    Samsung Bioepis Co., Ltd.

    Ansan

    Recruiting

  • A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants

    Phase

    N/A

    Span

    179 weeks

    Sponsor

    Eisai Korea Inc.

    Ansan

    Recruiting

  • Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination

    1. Safety - Incidence of fever (temperature ≥39.0℃) within 42 days after the IP administration - Incidence of fever (temperature ≥39.0℃) within 7 days after the IP administration - Solicited local/systemic AEs occurred within 7 days after the IP administration - Unsolicited adverse events that occurred within 42 days after the IP administration - Serious adverse events that occurred within 1 year after the IP administration - Vital signs and physical examinations 2. Efficacy (Immunogenicity) -GMT(Geometric Mean Titer) and GMR(Geometric Mean Ratio(fold change))measured by the glycoprotein enzyme-linked immunosorbent assay (gpELISA) at before and 42 days after the IP administration 3. Exploratory assessment - GMV and GMR of VZV-CMI response measured by INF-r ELISPOT at before and 42 days after the IP administration - GMT and GMR of the antibody titer measured by gpELISA at before and after the IP administration for 3 years - Varicella-like rash and Varicella-zoster virus genotyping analysis occurred after IP administration for 3 years

    Phase

    2

    Span

    261 weeks

    Sponsor

    Green Cross Corporation

    Ansan

    Recruiting

    Healthy Volunteers

  • A Phase 3 Study to Assess the Efficacy and Safety of PK101 in Patients With Knee Osteoarthritis

    The primary purpose of this study is to evaluate the efficacy of PK101 compared with PK101-002 at Week 8 in osteoarthritis. Also evaluates the safety of PK101.

    Phase

    3

    Span

    43 weeks

    Sponsor

    PMG Pharm Co., Ltd

    Ansan

    Recruiting

  • Drug-Coated Balloon in Patients With High Bleeding Risk

    Second-generation DES is the standard of care for patients with coronary artery disease who are deemed eligible for percutaneous coronary intervention (PCI). Despite many advantages, DES inevitably accompany disadvantages such as the occurrence of late stent thrombosis and the need for maintaining dual antiplatelet (DAPT) for certain period due to permanent vascular implant, which lead to both increased ischemic and bleeding events. As an alternative to DES, drug-coated balloon (DCB), a novel treatment strategy, which has benefit of having shorter DAPT maintenance duration due to the absence of metallic scaffolds and polymers, has been introduced. Based on meta-analysis based on many randomized clinical trials (RCT), its use has been established in in-stent restenosis of bare-metal stents (BMS) and DES. Furthermore, recently published RCT demonstrated efficacy and safety of DCB in de-novo coronary lesions in small vessels with reference vessel size<3.0mm. However, studies exploring the feasibility of DCB in de-novo coronary artery stenosis beyond small vessels are limited. Furthermore, there is scarce data comparing DCB with DES in patients with de-novo coronary artery stenosis and high bleeding risk (HBR), a situation in which long-term maintenance of DAPT is a clinical dilemma. In previous BASKET-SMALL 2 trial, DCB showed noninferiority to DES in patients with de-novo coronary artery stenosis and small vessel disease. However, this trial was conducted in non-HBR patients, and the number of participated patients was insufficient. In another RCT, DEBUT trial exclusively enrolled patients with HBR and de-novo coronary artery stenosis. Although the DEBUT trial showed superiority of DCB angioplasty over implantation of BMS to treat de-novo coronary artery stenosis in patients with HBR, the results could not be applicable in contemporary practice because BMS has been no longer in clinical use. Recently, multiple RCTs have proved short-term DAPT (1-3 months) has comparable efficacy to longer term DAPT in HBR patients using latest second-generation DES. On this background, the current trial aims to compare clinical outcomes between DCB and DES to treat de-novo coronary artery stenosis in patients with HBR receiving guideline-directed short-term DAPT.

    Phase

    N/A

    Span

    336 weeks

    Sponsor

    Samsung Medical Center

    Ansan

    Recruiting

1-10 of 16
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 609.945.0101

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information